Daily Soy Isoflavone Supplement Presents No Risks For Healthy Postmenopausal Women

A randomized two-year clinical trial involving 403 healthy postmenopausal women has found that a daily 80-120 mg supplement of soy hypocotyl isoflavones does not present a health risk, and may actually protect against cancer. The trial was designed to test the impact of soy isoflavone supplementation on osteoporosis, but researchers were also trying to determine if long-term supplementation led to adverse health outcomes. Only two women in the soy supplement groups  experienced serious health problems: one case of breast cancer and one case of endometrial cancer. This “was less than the expected population rate for these cancers,” the researchers said. The supplement used in the study was the patented soy germ isoflavone product SoyLife from Frutarom.